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Matrix metalloproteinase 9Abstract Background: Asthma is an airway inﬂammatory disease with functional and structural
changes, leading to bronchial hyperresponsiveness and airﬂow obstruction. Pathological repair of
the airways leads to these structural changes referred as airway remodeling. Matrix metalloprotein-
ases (MMPs) are extracellular degrading enzymes that play a critical role in the remodeling process.
Aim of the study: Is to study matrix metalloproteinase-9 in asthmatic patients, detecting its path-
ogenic role in airway remodeling.
Subjects and methods: Samples of broncho-alveolar lavage (BAL) ﬂuid and bronchoscopic biop-
sies from 30 asthmatic patients (10 mild, 10 moderate and 10 severe) and 10 healthy volunteers were
assessed for the levels of matrix metalloproteinase-9 (MMP-9) total and differential cell count (in
BAL ﬂuid), histological airway remodeling changes and immunohistochemical expression of
MMP-9 (in mucosal biopsies).
Results: BAL and tissue MMP-9 (going hand in hand with airway remodeling changes) were
higher in asthmatic patients and it was signiﬁcantly increased with increased severity. BAL total cell
count is higher in asthmatic patients. BAL eosinophils, neutrophils, lymphocytes as well as MMP-9
positive cell count were higher in asthmatic patients and increased with severity. MMP-9 tissue
expression was also strongly inversely correlated with the spirometric parameters in asthmatic
patients.
Conclusions: MMP-9 plays a role in airway inﬂammation and airway remodeling in asthma.
MMP-9 is an important player in airway remodeling in bronchial asthma and may be the link
between inﬂammation and remodeling processes.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Open access under CC BY-NC-ND license.Introduction
Asthma is a chronic disease of the lower airways characterized
by airway inﬂammation, reversible airﬂow limitation, and
bronchial hyperresponsiveness (BHR) [1].
756 A.A. Farhat et al.Deaths from asthma continue to occur in spite of our
increased understanding of the pathophysiology of asthma,
the availability of more effective medications for the control
of airway inﬂammation and improved asthma education [2].
Such patients who die from asthma demonstrate thickened
airway walls due to an increase in smooth muscle mass, inﬁl-
tration with inﬂammatory cells, deposition of connective tis-
sue, vascular changes and mucous gland hyperplasia, a
condition that termed airway remodeling [3,4].
Mechanisms controlling the pathogenesis of airway remod-
eling are poorly understood. One of such mechanisms is the
imbalance between extra cellular matrix (ECM) production
and collagen degradation [5].
Matrix metalloproteinases (MMPs) are enzymes playing
central roles in the turnover of ECM components as well as tis-
sue degradation, repair mechanisms and cell migration. Matrix
metalloproteinase-9 (MMP-9) is a 92-kDa metalloproteinase
also known as gelatinase B. It belongs to a group of gelatinases
that has received special interest because of their ability to
degrade elastin and also type IV collagen [6].
Although many intrinsic lung cells can be stimulated to
produce MMP-9, inﬂammatory cells are thought to be the
primary source of MMP-9 in disease [7,8].
Aim of the work
The aim of this work was to study matrix metalloproteinase-9
in asthmatic patients, detecting its role in the pathogenesis of
airway remodeling.
Subjects and methods
This study was carried out on 30 asthmatic patients and 10
non-smoker healthy volunteers (control group). Subjects of
the study were selected from patients who admitted in the
Chest Department, Tanta University Hospitals during the per-
iod from January 2012 to May 2013.
Subjects were classiﬁed into four groups; 10 healthy indi-
viduals as control (Group I), 10 patients with mild persistent
asthma who had nighttime symptoms not more than twice
per month., FEV1 or PEF > 80% predicted (Group II), 10
patients with moderate persistent asthma who had nighttime
symptoms more than once per week but not nightly,
FEV1 > 60% but <80% (Group III) and 10 patients with
severe persistent asthma who had often nightly symptoms,
FEV1 < 60% (Group IV) [7].
Neither the normal control subjects nor the patients with
chronic persistent asthma had any history of respiratory infec-
tion for at least 4 weeks before the study, and none of the par-
ticipants smoked. This study was performed with the approval
of the Ethics Committee of the Faculty of Medicine, Tanta
University Hospital, and informed written consent was
obtained from all enrolled subjects.
After thorough history taking and complete physical exam-
ination, all subjects underwent Chest X-ray (PA and lateral
views), ventilatory function tests (including: FVC, FEV1,
FEV1/FVC, and PEFR), bronchoalveolar lavage (BAL) that
was collected for total and differential inﬂammatory cell count,
and for the estimation of MMP-9 (using a MMP-9 ELISA
kit)[8] and ﬁnally, a bronchoscopic biopsy that was taken for
histopathological examination and estimation of MMP-9 byimmunohistochemistry using a Rabbit anti-human polyclonal
antibody against MMP-9 (Ab-9), ((catalog # RB-9234-P),
Lab Vision; Fremont, USA) with overnight incubation at
4 C after microwave antigen retrieval in 10 mM sodium cit-
rate buffer (pH 6.0) [9]. Evaluation of the immunohistochem-
ical results was done by Leica image analysis software and the
number of MMP-9 +ve cells was standardized to square mil-
limeter of tissue section surface area [10].
Results
The subjects of our study were classiﬁed into four groups. The
mean values of age were; 25.1 ± 4.5 (Group I), 36.3 ± 6
(Group II), 38.3 ± 6.4 (Group III), and 33.6 ± 4.8 (Group
IV) with no signiﬁcant differences. Spirometry was done for
all subjects, measuring FVC, FEV1, FEV1/FVC, and PEFR
(Table 1).
Bronchoalveolar lavage was done for all studied subjects to
assess the total inﬂammatory cell count/mm3, and percentage
of eosinophils and neutrophils, and to assess levels of MMP-
9 (ng/ml).
The mean values of BAL total cell count were
157.3 ± 28.01 · 103, 158.3 ± 32.3 · 103, 176.9 ± 32.8 · 103
and 200.2 ± 35.3 · 103 in groups I, II, III and IV respectively,
with a signiﬁcant increase in group IV compared with groups I,
II and III.
The mean values of the BAL eosinophils% were
0.49 ± 0.14, 0.97 ± 0.36, 1.26 ± 0.37 and 2.08 ± 0.53 in
groups I, II, III and IV respectively, with a signiﬁcant increase
in groups II, III and IV compared with group I, in groups III
and IV compared with group II and in group IV compared
with group III.
The mean values of the BAL neutrophils% were
0.68 ± 0.19, 0.70 ± 0.14, 1.46 ± 0.30 and 2.65 ± 0.41 in
groups I, II, III and IV respectively, with a signiﬁcant increase
in groups III and IV compared with group I, in groups III and
IV compared with group II and in group IV compared with
group III.
The mean values of MMP-9 were 23.7 ± 3.77,
57.6 ± 10.12, 65.4 ± 12.81 and 131.2 ± 21.56 ng/ml in groups
I, II, III and IV respectively, with a signiﬁcant increase in
groups II, III and IV compared with group I, and in group
IV compared with groups II and III (Table 2).
Bronchial biopsy was taken for both histopathological
examination and MMP-9 estimation by immunohisto-
chemistry.
Histopathological examination showed airway structural
changes in asthmatic patients, ranging from thickened base-
ment membrane with loss of surface epithelium (epithelial
shedding) in patients with mild asthma, to respiratory epithe-
lial hyperplasia, marked basement membrane thickening,
hypertrophy and hyperplasia of the airway smooth muscle
cells, and hyperplasia of the mucus glands, angiogenesis, and
increased collagen deposition in the sub epithelial layer in
patients with severe asthma (Fig. 1).
MMP-9 immune reactivity in the lung tissues showed
absence of MMP-9 positivity in the epithelium with negative
submucosa in group I, mild positivity in the epithelium with
negative submucosa in group II (MMP-9 +ve cells/
mm2 = 41.8 ± 4.77), moderate positivity in the epithelium
and the underlying structures as the submucosa and the
Table 1 Mean (±SD) values and statistical comparison of age and studied spirometric parameters in the four groups.
G.I G.II G.III G.IV
Age 25.1 ± 4.5 36.3 ± 6 38.3 ± 6.4 33.6 ± 4.8
f. test 0.635
P 0.558
FVC 99.5 ± 5.12 93.8 ± 6.84 90.2 ± 5.88 76.1 ± 10.72
f. test 5.36
P 0.008
FEV1 99.9 ± 5.54 89.6 ± 4.24 71.1 ± 4.81 52.6 ± 5.08
f. test 17.523
P 0.001
FEV1/FVC 101.3 ± 4.76 83.1 ± 7.90 71.4 ± 6.67 68.2 ± 7.91
f. test 46.702
P 0.001
PEFR 103.1 ± 5.87 94.1 ± 6.52 71.6 ± 4.19 59.0 ± 5.35
f. test 132.816
P 0.001
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Figure 1 Marked remodeling changes (group IV, severe asthma): [A] respiratory epithelial hyperplasia (EP), thickened basement
membrane (BM), hypertrophy of smooth muscle cells (SM), and hyperplasia of the mucus glands (G), [B] other areas showed widening of
the submucosa with marked inﬂammation, angiogenesis (BV), thickening of basement membrane (BM) and partially denuded surface
epithelium (EP) (·40; H&E).
Table 2 Mean (± SD) values and statistical comparison of BAL total cell count, eosinophils%, and neutrophils% in the four groups.
G.I G.II G.III G.IV
Total cell count · 103 157.3 ± 28.01 158.3 ± 32.3 176.9 ± 32.8 200.2 ± 35.3
f. test 3.225
P 0.016
Tukey’s test G.I&II G.I&III G.I&IV G.II&III G.II&IV GIII&IV
0.945 0.142 0.005 0.255 0.006 0.002
Eosinophils% 0.49 ± 0.14 0.97 ± 0.36 1.26 ± 0.37 2.08 ± 0.53
f. test 6.335
P 0.001
Tukey’s test G.I&II G.I&III G.I&IV G.II&III G.II&IV G.III&IV
0.001 0.001 0.001 0.001 0.001 0.001
Neutrophils% 0.68 ± 0.19 0.70 ± 0.14 1.46 ± 0.30 2.65 ± 0.41
f. test 9.336
P 0.001
Tukey’s test G.I&II G.I&III G.I&IV G.II&III G.II&IV G.III&IV
0.877 0.001 0.001 0.001 0.001 0.001
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Figure 2 Marked positivity for MMP-9 (Group IV; severe asthma) in the epithelium, submucosa [A and B] and the underlying smooth
muscle [A] (·40; immunoperoxidase for MMP-9).
Figure 3 Correlation between FEV1 % predicated and BAL
MMP-9 in the studied groups.
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muscles in group III (MMP-9 +ve cells/mm2 = 57.1 ±
8.74), and marked positivity for MMP-9 in the epithelium,
submucosa and the underlying smooth muscle in group IV.
(MMP-9 +ve cells/mm2 = 94.1 ± 11.9) (Fig. 2). MMP-9
+ve cell counts per mm2 showed a signiﬁcant difference
between groups, being the highest in severe asthma and the
lowest in mild asthma (p< 0.001). MMP-9 immune reactivity
was strongly inversely correlated with spirometric parameters
in asthma patient groups (p< 0.001).
Correlation of BAL MMP-9 concentration, (ng/ml) and
FEV1% predicted in the four studied groups showed a signif-
icant negative correlation (r= 0.764, p< 0.05) (Fig. 3).
Discussion
This work aimed to study matrix metalloproteinases-9 in
asthmatic patients, detecting its pathogenic role in airway
remodeling.
In this study, we have demonstrated that BAL total cell
count is increased in patients with asthma compared with
healthy subjects. There was a signiﬁcant increase in patients
with severe asthma compared with mild and moderate asth-
matics. Also, in our study there was a signiﬁcant increase in
the BAL eosinophils in patients with asthma compared with
healthy subjects. There was a signiﬁcant increase in patientswith severe asthma compared with mild and moderate asth-
matics, and in patients with moderate asthma compared with
patients with mild asthma. This association between eosino-
philia and outcomes of asthma severity has been conﬁrmed
and extended in several other studies that have shown that
BAL eosinophil numbers are the highest in patients with more
severe asthma [11–14].
In this study, there was a signiﬁcant increase in BAL neu-
trophils in patients with asthma compared with healthy sub-
jects. Also, there was a signiﬁcant increase in patients with
moderate and severe asthma compared with mild asthmatics.
Some studies concluded that increased neutrophil levels have
been found in patients with acute or persistent asthma com-
pared with controls, especially in patients with low numbers
of eosinophils and poor response to inhaled corticosteroids
[15–18].
The present study showed a signiﬁcant increase in BAL
ﬂuid MMP-9 in patients with asthma compared with control
subjects and in patients with severe asthma than in patients
with mild to moderate asthma. Such increased BAL MMP-9
levels showed a signiﬁcant positive correlation between
MMP-9 concentration and BAL total cell count in patients
with asthma, regardless of the degree of severity. Such ﬁnding
explained that the main cellular sources of MMP-9 are the
inﬂammatory cell inﬁltrates rather than resident ones.
There was a signiﬁcant positive correlation between BAL
MMP-9 concentration and BAL eosinophils in patients with
asthma denoting that asthma is an inﬂammatory disease
mainly eosinophilic in nature.
Also, as a unique ﬁnding, there was a signiﬁcant positive cor-
relation betweenMMP-9 concentration and neutrophils in BAL
only in patients with severe asthma. These data may speculate
that neutrophil inﬂux is the main source of increased MMP-9
in patients with severe asthma and deserves further research.
In our study, healthy subjects showed nearly-normal airway
structure, but asthmatic patients showed structural airway
changes even in patients with mild asthma. This implies that
the structural changes of airway remodeling occur at the same
time as the onset of airway inﬂammation. Coinciding with
these structural changes, airways showed mild positivity for
MMP-9 in the epithelium with negative submucosa in mild
asthmatic patients, moderate positivity in the epithelium and
the underlying structures as the submucosa and the underlying
Role of matrix metalloproteinase-9 in asthmatic patients 759muscles, hyperplastic mucous glands and smooth muscles in
the moderate asthmatic patients, marked positivity for
MMP-9 in the epithelium, submucosa and the underlying
smooth muscle in severe asthmatic patients. The MMP-9
immunoreactivity was the highest in the severe asthma group
followed by the moderate asthma group and the lowest in
the mild asthma group. Moreover MMP-9 tissue immunoreac-
tivity was strongly inversely correlated with the spirometric
parameters, a ﬁnding that stands with the important role of
MMP-9 in airway remodeling. So, targeting MMP-9 in asthma
patient may have an important role in delaying or stopping air-
way remodeling and avoiding its bad consequences on the
patient.
Conclusions
Increased inﬂammatory burden coincides with increased level
of proteinases especially MMP-9 in the airways. Increased
MMP-9 burden in the airways could result in ECM destruc-
tion and contribute to airway remodeling and decline in lung
functions in asthmatic patients.
Recommendation
Increased MMP-9 levels in the airways could detect a subset of
asthmatic patients with MMP-9 dependent remodeling, allow-
ing early detection and early treatment of these alterations that
may be of beneﬁcial value in the prognosis of asthmatic
patients.
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